השוואת שיטות
סקרו את השיטות שבחרתם זו לצד זו; שורות שבהן יש הבדל מודגשות.
| שאלון השפעת נשירת שיער (ALPPQ)× | Skindex-29 (כלי להערכת איכות חיים במחלות עור)× | |
|---|---|---|
| תחום | דרמטולוגיה | דרמטולוגיה |
| משפחה | Process / pipeline | Process / pipeline |
| שנת המקור≠ | 2014 | 1997 |
| הוגה השיטה≠ | Gupta AK, Strober BE et al. | Chren MM, Lasek RJ |
| סוג | Self-report | Self-report |
| מקור מכונן≠ | Gupta AK, Talukder M. Alopecia areata: autoimmune basis of hair loss and available treatment options. Can J Dermatol. 2014;12(5):289-304. link ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| כינויים | Hair Loss Impact Questionnaire, Alopecia Areata QoL | Skindex, Skindex-QoL |
| קשורות≠ | 4 | 1 |
| תקציר≠ | The Hair Loss Impact Questionnaire (Alopecia Areata Patient Priority Outcomes Questionnaire, ALPPQ) is a disease-specific, patient-administered quality-of-life measure assessing the psychosocial and functional burden of alopecia areata, a chronic autoimmune disorder causing patchy hair loss. Alopecia areata affects appearance, self-esteem, and social functioning disproportionately, often causing depression and anxiety. The ALPPQ captures these impacts, ensuring that treatment efficacy encompasses meaningful quality-of-life outcomes. It is increasingly used in clinical trials and observational studies of alopecia areata therapeutics. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGateמערך נתונים ↗ |
|
|